Back to Browse Journals » International Journal of Nephrology and Renovascular Disease » Volume 1

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs

Authors James B Wetmore, L Darryl Quarles

Published 13 November 2008 Volume 2008:1 Pages 5—17


Review by Single-blind

Peer reviewer comments 7

James B Wetmore1, L Darryl Quarles1,2

1Department of Medicine, Division of Nephrology, University of Kansas Medical Center, Kansas City, KS, USA; 2The Kidney Institute, University of Kansas Medical Center, Kansas City, KS, USA

Abstract: There is a growing understanding of the pathophysiology of secondary hyperparathyroidism (SHPT) and a recent emergence of new agents for SHPT treatment in patients with advanced kidney disease. At the same time, appreciation that mineral metabolic derangements promote vascular calcification and contribute to excess mortality, along with recognition of potentially important “non-classical” actions of vitamin D, have prompted the nephrology community to reexamine the use of various SHPT treatments, such as activated vitamin D sterols, phosphate binders, and calcimimetics. In this review, the evidence for treatment of SHPT with calcimimetics and vitamin D analogs is evaluated, with particular consideration given to recent clinical trials that have reported encouraging findings with cinacalcet use. Additionally, several controversies in the pathogenesis and treatment of SHPT are explored. The proposition that calcitriol deficiency is a true pathological state is challenged, the relative importance of the vitamin D receptor and the calcium sensing receptor in parathyroid gland function is summarized, and the potential relevance of non-classical actions of vitamin D for patients with advanced renal disease is examined. Taken collectively, the balance of evidence now supports a treatment paradigm in which calcimimetics are the most appropriate primary treatment for SHPT in the majority of end stage renal disease patients, but which nevertheless acknowledges an important role for modest doses of activated vitamin D sterols.

Keywords: secondary hyperparathyroidism, vitamin D, vitamin D receptor, calcium sensing receptor, calcimimetics, kidney disease

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Effects of titania nanotubes with or without bovine serum albumin loaded on human gingival fibroblasts

Liu X, Zhou X, Li S, Lai R, Zhou Z, Zhang Y, Zhou L

International Journal of Nanomedicine 2014, 9:1185-1198

Published Date: 6 March 2014

Efficacy of various antioxidants in the protection of the retinal pigment epithelium from oxidative stress

Kagan DB, Liu H, Hutnik CML

Clinical Ophthalmology 2012, 6:1471-1476

Published Date: 7 September 2012

Update on the diagnosis and management of acute kidney injury

Ali Akcay, Kultigin Turkmen, DongWon Lee, et al

International Journal of Nephrology and Renovascular Disease 2010, 3:129-140

Published Date: 29 September 2010

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension

Peter Bramlage

Vascular Health and Risk Management 2009, 5:213-224

Published Date: 11 February 2009

Vision loss associated with the use and removal of intraocular silicone oil

Patrick D Williams, Christopher G Fuller, Ingrid U Scott, Dwain G Fuller, Harry W Flynn Jr

Clinical Ophthalmology 2008, 2:955-959

Published Date: 5 December 2008

Ambrisentan for the treatment of pulmonary arterial hypertension

Brian Casserly, James R Klinger

Drug Design, Development and Therapy 2008, 2:265-280

Published Date: 4 December 2008

Potential bias in ophthalmic pharmaceutical clinical trials

Paul Varner

Clinical Ophthalmology 2008, 2:401-411

Published Date: 6 June 2008

Clinical findings following Ahmed Glaucoma Valve™ implantation in pediatric glaucoma

Amir Pirouzian, Joseph L Demer

Clinical Ophthalmology 2008, 2:123-127

Published Date: 7 March 2008

Severe supraaortal atherosclerotic disease resembling Takayasu’s Arteritis

Bernhard Kis, Thomas Liebig, Peter Berlit

Vascular Health and Risk Management 2007, 3:351-354

Published Date: 15 July 2007